For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon Renamed “Sumitomo Pharma”
April 4, 2022
- COVID-19 as Catalyst for Introducing Decentralized Clinical Trials in Japan; Some Results Due Out by Year-End
April 1, 2022
- Akebia/Otsuka’s HIF-PH Inhibitor Vadadustat Nixed in US
April 1, 2022
- Asahi Kasei Grabs Japan Rights to VectivBio’s GLP-2 Analog Peptide
April 1, 2022
- Kobayashi Kako Manufacturing Unit Now Under Sawai; 170 Staffers Remain for Compensation, Drug Handover
April 1, 2022
- Daiichi Sankyo to Offload Cravit Business in China to Local Firm
April 1, 2022
- Sumitomo Dainippon Kicks Off PI/II Study for AML Drug
April 1, 2022
- Ono Bags Global Rights to Numab’s Multispecific I/O Antibody
April 1, 2022
- Healios’ Cell Processing Center in Kobe to Begin Full Operations in Mid-2022
March 31, 2022
- Sandoz to Exclusively Sell Nichi-Iko’s Avastin Biosimilar in Japan
March 31, 2022
- Sumitomo Dainippon to Set Up Holding Firm in China
March 31, 2022
- Pfizer Files Precedex for New Pediatric Indication as “Specific Use Drug”
March 31, 2022
- Ono Collaborates with French Startup in AI-Based Drug Discovery
March 31, 2022
- Kyorin Ties Up with US Biotech for Drug Discovery Research Using Protein Engineering
March 31, 2022
- Taiho’s Biliary Cancer Med Gets US FDA’s Priority Review
March 31, 2022
- Ube, iPSC Startup to Develop IPF Drug, Eyes Clinical Trial in FY2023
March 30, 2022
- MSD Says to Ensure HPV Vaccine Supply in Japan, 4 Million-Plus Syringes for FY2022
March 30, 2022
- JCR to Focus on Partnerships as Core of Growth Strategy: Vice President
March 30, 2022
- Novartis Stepping Up Population Health Initiatives in CV, Oncology Arenas to Solve Regional Challenges
March 30, 2022
- JCR, Takeda Seal R&D Pact on Gene Therapies Using BBB Technology
March 29, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…